B. Guérette

发表

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation.

J. Tremblay, D. Skuk, M. Entman, 1997, Cell transplantation.

Prevention by anti-LFA-1 of acute myoblast death following transplantation.

C. Huard, D. Skuk, B. Roy, 1997, Journal of immunology.

Myoblast Transplantation : a Brief Review of the Problems and of Some Solutions

J. Tremblay, B. Guérette, J. Tremblay, 2007 .

FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer.

C. Gravel, R. Roy, I. Kinoshita, 1995, Human gene therapy.

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis

D. M. van der Heijde, R. Landewé, J. Smolen, 2015, Arthritis Research & Therapy.

Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection

J. Huard, R. Roy, B. Guérette, 1994, Muscle & nerve.

Clinical, Functional, and Radiographic Benefits of Longterm Adalimumab Plus Methotrexate: Final 10-year Data in Longstanding Rheumatoid Arthritis

D. M. van der Heijde, E. Keystone, A. Kavanaugh, 2013, The Journal of Rheumatology.

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open‐label, multicentre, phase IIIb study

K. Papp, C. Lynde, B. Guérette, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Resting Lymphocyte Kinase (Rlk/Txk) Targets Lymphoid Adaptor SLP-76 in the Cooperative Activation of Interleukin-2 Transcription in T-cells*

H. Schneider, C. Rudd, B. Guérette, 2000, The Journal of Biological Chemistry.

Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

K. Mchugh, J. Chao, E. Loftus, 2011, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Inflammatory damage following first‐generation replication‐defective adenovirus controlled by anti‐LFA‐1

C. Huard, C. Gravel, P. Moisset, 1997, Journal of leukocyte biology.

Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig.

C. Gravel, K. Wood, J. Vilquin, 1996, Human gene therapy.

Very efficient myoblast allotransplantation in mice under FK506 immunosuppression

R. Roy, J. Vilquin, B. Guérette, 1994, Muscle & nerve.

Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice.

R. Roy, B. Guérette, J. Tremblay, 1996, Transplantation.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies

D. Gladman, E. Lespessailles, J. Gómez-Reino, 2018, RMD Open.

Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study

D. Gladman, J. Sampalis, B. Guérette, 2010, The Journal of Rheumatology.

RCAS1 is associated with ductal breast cancer progression.

J. Rousseau, C. Doillon, M. Audette, 2002, Biochemical and biophysical research communications.

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

B. Strober, M. Lebwohl, A. Menter, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Control of Inflammatory Damage by Anti-Lfa-1: Increase Success of Myoblast Transplantation

D. Skuk, M. Entman, B. Guérette, 1997 .

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

D. Gladman, P. Mease, G. Schett, 2019, Arthritis Research & Therapy.

AB0741 ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST

L. Coates, A. Ogdie, A. Orbai, 2019, Abstracts accepted for Publication.

FRI0450 PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST

D. Gladman, A. Ogdie, P. Mease, 2019, Psoriatic arthritis.

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials

D. Gladman, P. Mease, I. McInnes, 2021, Rheumatology and Therapy.

Quantification of normal dystrophin mRNA following myoblast transplantation in mdx mice

R. Roy, J. Vilquin, B. Guérette, 1995, Muscle & nerve.

Lymphocyte infiltration following allo‐and xenomyoblast transplantation in mdx mice

R. Roy, J. Vilquin, B. Guérette, 1995, Muscle & nerve.

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis

P. Emery, A. Kavanaugh, J. Smolen, 2017, Annals of the rheumatic diseases.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

P. Emery, K. Pavelka, L. Redden, 2014, The Lancet.

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

P. Emery, L. Redden, A. Kavanaugh, 2012, Annals of the rheumatic diseases.

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

D. M. van der Heijde, R. Landewé, E. Keystone, 2012, Annals of the rheumatic diseases.

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

E. Keystone, B. Haraoui, B. Guérette, 2011, BMC musculoskeletal disorders.

Increased interferon‐γmRNA expression following alloincompatible myoblast transplantation is inhibited by FK506

R. Roy, J. Vilquin, B. Guérette, 1996, Muscle & nerve.

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients.

C. Edwards, A. Wells, A. Kivitz, 2021, Rheumatology.

Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results

A. Ogdie, L. Harrold, P. Mease, 2020, The Journal of Rheumatology.

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations

L. Coates, D. Gladman, A. Ogdie, 2020, Arthritis care & research.

INCREASED GRANZYME B mRNA AFTER ALLOINCOMPATIBLE MYOBLAST TRANSPLANTATION

J. Puymirat, R. Roy, B. Guérette, 1995, Transplantation.

Successful myoblast allotransplantation in mdx mice using rapamycin.

R. Roy, J. Vilquin, B. Guérette, 1995, Transplantation.

Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study

R. Moots, P. Salkovskis, Yulia Goryachev, 2012 .

Myoblast transplantations lead to the expression of the laminin α2 chain in normal and dystrophic (dy/dy) mouse muscles

J. Puymirat, M. Fiszman, M. Fardeau, 1999, Gene Therapy.